ReviewMycopathologia2014
MALDI-TOF mass spectrometry: any use for Aspergilli?
Review in Mycopathologia, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Validation of the Mycelium Transfer Method Coupled with MALDI-TOF MS for Rapid Identification of Filamentous Fungi.Pathogens (Basel, Switzerland) · 2026Article
- Detection of Fluconazole Resistance inJournal of fungi (Basel, Switzerland) · 2025Article
- Identification of Filamentous Fungi: An Evaluation of Three MALDI-TOF Mass Spectrometry Systems.Mycoses · 2025Article
- Comparison of the BluePoint MoldID oligonucleotide array and Bruker Biotyper MALDI-TOF MS for the identification of filamentous fungi.Journal of clinical microbiology · 2025Article
- Hospital distribution, seasonality, time trends and antifungal susceptibility profiles of all Aspergillus species isolated from clinical samples from 2015 to 2022 in a tertiary care hospital.BMC microbiology · 2024Article
- Fungal Septic Knee Arthritis Caused byDiagnostics (Basel, Switzerland) · 2021Article
- Identification and in vitro antifungal susceptibility of causative agents of onychomycosis due to Aspergillus species in Mashhad, Iran.Scientific reports · 2021Article
- Multilaboratory Evaluation of the MALDI-TOF Mass Spectrometry System, MicroIDSys Elite, for the Identification of Medically Important Filamentous Fungi.Mycopathologia · 2021Article
- An exploratory MALDI-TOF MS library based on SARAMIS superspectra for rapid identification ofMycoscience · 2021Article
- Epidemiology and Diagnostic Perspectives of Dermatophytoses.Journal of fungi (Basel, Switzerland) · 2020Review
- Performance and Application of 16S rRNA Gene Cycle Sequencing for Routine Identification of Bacteria in the Clinical Microbiology Laboratory.Clinical microbiology reviews · 2020Review
- Identification of clinical dermatophyte isolates obtained from Iran by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.Current medical mycology · 2019Article
- Machine Learning Approach forFrontiers in microbiology · 2019Article
- Azole Resistance in Aspergillus fumigatus in Patients with Cystic Fibrosis: A Matter of Concern?Mycopathologia · 2018Review
- Current State of the Diagnosis of Invasive Pulmonary Aspergillosis in Lung Transplantation.Frontiers in microbiology · 2018Review
- A Review of Diagnostic Methods for Invasive Fungal Diseases: Challenges and Perspectives.Infectious diseases and therapy · 2017Review
- Susceptibility Testing of Common and Uncommon Aspergillus Species against Posaconazole and Other Mold-Active Antifungal Azoles Using the Sensititre Method.Antimicrobial agents and chemotherapy · 2017Article
- Identification of Molds by Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry.Journal of clinical microbiology · 2017Review
- Performance of VITEK mass spectrometry V3.0 for rapid identification of clinicalInfection and drug resistance · 2017Article
- Evaluation of the Bruker Biotyper Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry System for Identification ofFrontiers in microbiology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently, relentless efforts to develop rapid, cost-effective, and reliable laboratory methods for daily diagnosis of fungal diseases such as aspergillosis appear to be materialized in the relatively new, but revolutionary matrix-assisted laser desorption ionization-time-of-flight (MALDI-TOF) mass spectrometry (MS) technology. As for Aspergilli, MALDI-TOF MS profiling of isolates growing in culture--characteristic protein spectra are obtainable by means of simple and reproducible preanalytical and analytical procedures--ensures that single species within the different sections or complexes can be easily and accurately identified, including species that are morphologically and phylogenetically similar to each other. Thus, resort to longer and more onerous molecular biology techniques is restricted to those cases for which no spectra in the reference fungal database or library are available at the time of analysis. However, it is necessary to interrogate reference libraries composed of spectra that have been obtained using procedures similar to those used to obtain the test isolate's mass spectrum, as well as to continuously update these libraries for enriching them with fungal strains/species not (or not well) represented in their current versions. Compared to mold identification, very limited work was reported on the use of MALDI-TOF MS to perform strain typing or antifungal susceptibility testing for Aspergilli. If these complementing areas will be potentiated in the near future, MALDI-TOF MS could effectively support the clinical microbiology/mycology laboratory in its primary role of assisting either infection control specialists or physicians for the diagnosis and treatment of aspergillosis.
Indexed as
Identifiers
25001870What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.